Optain Health, a healthcare technology company specializing in AI-driven disease detection, has closed an oversubscribed $26M Series A round led by Insight Partners, with participation from existing backers and seven major U.S. health systems, including Memorial Hermann, Northwell Health, Novant Health, Ohio State Wexner Medical Center, and UPMC.
The funding will accelerate Optain’s U.S. expansion and enterprise deployments, while also supporting international growth across Australia, Europe, the Middle East, and Southeast Asia. Built on more than a decade of research, Optain’s platform uses Oculomics technology — combining robotic retinal imaging and AI workflows — to detect conditions such as diabetic retinopathy, glaucoma, and AMD.
With this milestone, Optain positions itself at the forefront of equitable, accessible AI-powered screening to transform preventative healthcare worldwide.
